Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_2
3
75%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

withdrawn125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

NCT01580397
completedphase_2

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

NCT01514188
completedphase_1

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

NCT01337505
withdrawnphase_2

INNO-206 in Patients With Small Cell Lung Cancer (SCLC)

NCT00472771

Clinical Trials (4)

Showing 4 of 4 trials
NCT01580397Phase 2

Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

Completed
NCT01514188Phase 2

Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

Completed
NCT01337505Phase 1

Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

Completed
NCT00472771Phase 2

INNO-206 in Patients With Small Cell Lung Cancer (SCLC)

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4